Digital Therapeutics for Social Cognitive Function in Schizophrenia Spectrum Disorder: A Randomized Controlled Trial

Recruiting now · Not applicable

Conditions studied: Schizophrenia, Schizoaffecitve Disorder

In brief

The purpose of this study is to evaluate the safety and preliminary effectiveness of a smartphone-based digital therapeutic application (AffectUs) for improving social cognition, particularly emotion processing and social cue perception, in individuals with schizophrenia spectrum disorders. In this randomized controlled trial, participants will be assigned either to use AffectUs for 10 weeks in addition to treatment as usual or to receive psychoeducational materials and treatment as usual. Participants will complete assessments at baseline, week 5, week 10, and week 15 to evaluate social cognition, clinical outcomes, and safety.

Key facts

Study ID

NCT07755605

Run by

Samsung Medical Center

People needed

60

Starts

2026-07-15

Expected to finish

2027-03-01

Last updated by the study team

2026-08-10

Who can join

Age: 19 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Current or past diagnosis of intellectual disability.
• Initiation of or current participation in structured psychosocial interventions (e.g., cognitive behavioral therapy or social cognition training) within the past 3 months.
• Considered by the investigator to be at significant risk of suicide. 4, Pregnant or having a positive pregnancy test at screening.
• Any condition that, in the opinion of the investigator, would make participation unsafe or interfere with study participation or data interpretation.

Where it is running

• Samsung Medical Center — Seoul, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.